March 2026 Psychedelic Bill Roundup: federal and state updates on ibogaine research, trigger laws, and psilocybin program changes

U.S. psychedelic policy reform accelerated through March 2026 with 11 new bills across seven jurisdictions and major movement on many existing measures. Ibogaine research became the centerpiece of the month: Texas advanced its $50 million ibogaine research programme with an approach led by in-state medical research teams, after no suitable developer proposal was submitted. Mississippi then signed HB314 requiring its research consortium to coordinate with and use the same drug developer as a lead consortium in another state, effectively tying its effort to a Texas-anchored multistate network. The roundup also notes momentum in several other states, including signings or approvals of ibogaine related initiatives in places like Mississippi, Kentucky, and other jurisdictions, while West Virginia’s ibogaine research bill (HB4626) was vetoed. Other policy tracks gained ground as well, including continued expansion of “trigger law” activity in states such as South Dakota, Mississippi, and West Virginia, Oregon’s substantive modifications to its psilocybin programme, and Massachusetts legislative signals favoring regulated access over decriminalisation.